The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQALLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQALLR) and reminds investors of the November 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) --

Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. Allarity is a clinical-stage biopharmaceutical company.

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQALLR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). Investors have until November 12, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of GitLab Inc. (NASDAQGTLB), Allarity Therapeutics, Inc. NASDAQ: ALLRNASDAQALLR)(NASDAQ: ZINASDAQZI, and Agenus Inc. (NASDAQ: AGENNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Allarity Therapeutics, Inc. (NASDAQALLR), Metagenomi, Inc. NASDAQ: MGXNASDAQMGX)(NASDAQ: AGENNASDAQAGEN, and New Fortress Energy Inc. (NASDAQ:NFENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of against Allarity Therapeutics, Inc. (NASDAQALLR), Metagenomi, Inc. NASDAQ: MGXNASDAQMGX)(NYSE: FNANYSEFNA, and New Fortress Energy Inc. (NASDAQ:NFENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) --

Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on October 9, 2024, it received a formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”). The notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule 5550(a)(2) (the “Bid Price Rule”). Nasdaq noted that since September 11, 2024, Allarity’s stock has maintained a closing bid price of $1.00 or more for 20 consecutive trading days, thereby meeting the requirements for regaining compliance with the Bid Price Rule.

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of against Allarity Therapeutics, Inc. (NASDAQALLR), Metagenomi, Inc. NASDAQ: MGXNASDAQMGX)(NYSE: FNANYSEFNA, and New Fortress Energy Inc. (NASDAQ:NFENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of against Allarity Therapeutics, Inc. (NASDAQALLR), Metagenomi, Inc. NASDAQ: MGXNASDAQMGX)(NYSE: FNANYSEFNA, and New Fortress Energy Inc. (NASDAQ:NFENASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.